Stay updated with breaking news from Roche Graham. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Roche agreed to take over unlisted obesity drug developer Carmot Therapeutics for $2.7 billion upfront, joining a list of contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk and Eli Lilly.
For the Swiss drugmaker, deal marks a return to a GLP-1 field that it abandoned in 2018
By Adria Calatayud Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion as the Swiss pharmaceutical giant seeks to bolster its...
By Adria Calatayud Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion as the Swiss...